跳转至内容
Merck
CN

V0030000

缬氨酸

European Pharmacopoeia (EP) Reference Standard

别名:

L -缬氨酸, (S)-α-缬氨酸, L-2-氨基-3-二甲基丁酸

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

线性分子式:
(CH3)2CHCH(NH2)CO2H
化学文摘社编号:
分子量:
117.15
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
1721136
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


grade

pharmaceutical primary standard

API family

valine

manufacturer/tradename

EDQM

mp

295-300 °C (subl.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(C)[C@H](N)C(O)=O

InChI

1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1

InChI key

KZSNJWFQEVHDMF-BYPYZUCNSA-N

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括SDS和任何产品信息单均由药典颁发机构制定并发布。如需进一步信息和支持,请访问现行药典网站。

Application

缬氨酸EP参考标准品的预期用途是欧洲药典规定的实验室测试。

Packaging

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

Other Notes

可能适用相应的销售限制。


存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



Xin Zhang et al.
Hypertension (Dallas, Tex. : 1979), 64(1), 87-93 (2014-04-23)
Renovascular hypertension alters cardiac structure and function. Autophagy is activated during left ventricular hypertrophy and linked to adverse cardiac function. The angiotensin II receptor blocker, valsartan, lowers blood pressure and is cardioprotective, but whether it modulates autophagy in the myocardium
Thomas D Giles et al.
Lancet (London, England), 383(9932), 1889-1898 (2014-06-03)
The fixed-dose combination of any two antihypertensive drugs from different drug classes is typically more effective in reducing blood pressure than a dose increase of component monotherapy. We assessed the efficacy and safety of a fixed-dose combination of a vasodilating
K Aaboe et al.
Diabetes, obesity & metabolism, 17(1), 74-81 (2014-09-23)
To examine whether 12 weeks of treatment with a dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin, influences the insulin secretion induced by glucose, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) during a hyperglycaemic clamp in patients with type 2 diabetes (T2DM).



全球贸易项目编号

货号GTIN
V003000004061833801536